Skip to main content

Table 1 Baseline characteristics.

From: Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION study

  FPV Cohort (n = 105) SQV Cohort (n = 98)
% Male 74% 65%
Mean Age (years) 43 41
Primary HIV risk factor (%) IVDU (53%) IVDU (53%)
CDC C status (%) 44% 34%
Main reasons for TDF based regimen (%) Virological failure (59%) Virological failure (48%)
  Toxicity management (19%) Simplification (20%)
Previous time on ARV; Months. Median (IQR) 70 (21–111) 73 (34–111)
Most common acompanying NRTIs 3TC or FTC (36%) 3TC or FTC (65%)
  AZT or d4T (26%) AZT or d4T (7%)
  ddI (11%) ddI (13%)
Median BL HIV RNA, c/mL (log) 3.9 3.3
Mean BL CD4 count (cell/mm3) 335 387
  1. BL = Baseline; ARV = antiretrovirals.